For experimental validation, we chose the MYC TAD (Fig. 2A) because chromatin interactions between the MYC promoter region and various cell type-specific super enhancers (SEs) within this TAD have been thoroughly characterized across many common cancer cell lines [24, 30–36]. This evidence concerns the gene MYC and cancer.